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Abstract: Therapeutic effectiveness of treatments for ovarian cancer is not optimal. PDCD-1 and CTLA-4 offers the 
potential as a prognostic marker in addition to being a target for therapy. To assess the prognostic roles of PDCD-1 
and CTLA-4 Gene in ovarian cancer, we utilized the Kaplan Meier plotter, a biomarker assessment tool with large 
quantities of data. The relationship between PDCD-1 and overall survival (OS) as well as CTLA-4 and OS were pre-
sented using Hazard Ratio, 95% CI and logrank P value. Then gene expression level was compared using H-Test and 
U test. The results were as follows: PDCD-1 and CTLA-4 gene expressions among 1582 ovarian cancer patients were 
shown with median gene expression value as the cut-off. Expression of PDCD-1 and CTLA-4 did not differ with regard 
to stages and P53 gene mutation. But the expression of CTLA-4 was higher in endometrioid than in serous cancer 
patients. Different grades of both PDCD-1 and CTLA-4 had different mean values. Higher expression of the PDCD-1 
was not significantly correlated with better OS with HR 0.88 (95% CI: 0.77-1.01, P=0.061) but higher CTLA-4 was 
associated with better survival with HR 0.84 (95% CI: 0.73-0.96, P=0.0099) on the transcriptome level. In conclu-
sion, lower expression of CTLA-4, but not PDCD-1 predicts worse survival. 
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Introduction
Ovarian cancer (OC) is a kind ofmalignant tumor 
of the female reproductive system. It is the 
most common cause of death in women with 
gynecological malignancy which is responsible 
for the highest mortality among US women [1, 
2]. Despite extensive researches in this area, 
the therapeutic effectiveness of treatments for 
ovarian cancer is not optimal [3]. But recently, a 
large number of biomarker candidates have 
been suggested for predicting clinical out-
comes in ovarian cancer patients and have 
shown the potential in the treatment of OC [1, 
4-9].
Among them, the roles of PDCD-1 (Programmed 
cell death 1, also known as PD-1 and CD279) 
and CTLA-4 (cytotoxic T-lymphocyte-associated 
protein 4, also known as CD152) are brought 
forward in tumor progression and suppression. 
The translational products of PDCD-1 and 
CTLA-4 gene are PDCD-1 and CTLA-4, respec-
tively. PDCD-1 binds two ligands, PD-L1 (B7-H1) 
and PD-L2 (B7-DC) and can compete with B7.1, 
resulting in inhibition of T cell activation [10, 
11]. Cytotoxic T-lymphocyte-associated antigen 
4 (CTLA-4) is another immune inhibitory path-
way protein that results in T-cell down regula-
tion and can act as a co-inhibitory receptor with 
PDCD-1 [12].
Studies have suggested that some tumors have 
high levels of expression of PD-L1, possibly 
suppressing anti-tumor T cell responses [13]. 
Hamanishi J et al. [14] studied the expression 
of PD-L1 and PD-L2 on ovarian tumors and 
found a significantly worse overall survival (OS) 
in patients whose tumor expressed one or both 
of these ligands. It has been indicated that 
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PDCD-1/PD-L1 pathway (CD274) blockade aug-
ments tumor inhibition by increasing effector T 
cell activity, while attenuating Treg cell suppres-
sion [15]. The blockage and silencing of PDCD-
1, CTLA-4 or both PDCD-1 and CTLA-4 mole-
cules could significantly reduce arginase I activ-
ity and expression induced with tumor-associ-
ated factor [16]. As a result, PD-L1 offers the 
potential as a prognostic marker in addition to 
being a target for therapy. 
What’s more, blockade of PDCD-1, CTLA-4 or 
both slowed tumor growth and improved the 
survival rate of tumor-bearing mice. Monoclonal 
antibodies that bind such targets have been 
used to resist tumor. For example, FDA has 
approved αCTLA-4 antibody for treatment of 
melanoma [16].
However, the studies described above enrolled 
a relatively small number of patients and some 
of them appeared to be promising only in ani-
mal models without being confirmed in human 
clinical trials. Larger and more specific studies 
are required to define the prognostic roles. In 
this study, we estimated the prognostic roles of 
PDCD-1 and CTLA-4 Gene in ovarian cancer 
using a large-scale database. We utilized the 
Kaplan Meier plotter, a biomarker assessment 
tool, of which the large quantities of data are 
from the Gene Expression Omnibus (GEO) and 
the Cancer Genome Atlas (TCGA). 
Methods
Construction of ovarian cancer microarray da-
tabase
The way of the database’s (www.kmplot.com) 
construction was described in a previous report 
[37]. To summarize, we explored GEO (http://
www.pubmed.com/geo) and TCGA (http://can-
cergenome.nih.gov) to identify ovarian datas-
ets suitable for the analysis and extracted 
the data. Subtypes of ovarian cancer are avail-
able of different stages, histology, grades and 
P53 gene mutation. Detailed demographic and 
treatment information of each patient is not 
shown. Datasets included in the online data-
base are as follows: GSE14764, GSE15622, 
Table 1. A summary of the clinical characteristics of PDCD-1 and CTLA-4
PDCD-1 CTLA-4
N Mean 95% 
Conf. (±)
Std. 
Error
Std. 
Dev.
N Mean 95% 
Conf. (±)
Std. 
Error
Std. 
Dev.
Stage
    1 77 45.23 14.08 7.07 62.05 77 56.48 12.17 6.11 53.61 
    2 65 29.02 9.80 4.90 39.54 65 49.06 12.18 6.10 49.17 
    3 1004 60.54 6.11 3.11 98.65 1004 58.22 6.41 3.27 103.47 
    4 169 47.35 10.39 5.27 68.45 169 48.95 9.10 4.61 59.89 
    Entire sample 1315 56.39 4.96 2.53 91.62 1315 56.47 5.11 2.61 94.48 
Subtype (1_serous2_endometrioid)
    1 1143 44.72 4.49 2.29 77.44 1143 53.95 4.43 2.26 76.25 
    2 36 63.31 29.55 14.56 87.35 36 64.75 18.23 8.98 53.89 
    Entire sample 1179 45.28 4.44 2.27 77.79 1179 54.28 4.32 2.20 75.67 
Grade
    0 10 34.00 20.85 9.22 29.15 10 77.70 59.58 26.34 83.29 
    1 56 67.29 27.41 13.68 102.35 56 63.66 20.60 10.28 76.92 
    2 315 77.32 10.92 5.55 98.54 315 71.37 8.19 4.16 73.87 
    3 973 52.75 5.62 2.87 89.39 973 63.15 7.26 3.70 115.41 
    4 2 136.00 1651.81 130.00 183.85 2 23.00 228.71 18.00 25.46 
    Entire sample 1356 59.04 4.93 2.51 92.52 1356 65.13 5.62 2.86 105.46 
P53 mutation (1_mutated, 0_wild type)
    0 87 17.51 4.14 2.08 19.44 87 21.66 5.34 2.69 25.05 
    1 441 17.19 1.84 0.94 19.70 441 23.95 2.47 1.26 26.41 
    Entire sample 528 17.24 1.68 0.85 19.64 528 23.57 2.24 1.14 26.18 
PDCD-1 and CTLA-4
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GSE18520, GSE19829, GSE23554, GSE261- 
93, GSE26712, GSE30161, GSE3149, GSE- 
9891, GSE27651 and TCGA. All the microarray 
are based on transcriptome.
Data collection
To present the association between the gene 
under investigation and survival, we retrieved 
the data using gene expression cutoff value as 
median over entire dataset. We also excluded 
the biased arrays by checking if two or more 
of the following parameters were out of the 
95% range of all arrays: percentage of present 
calls, the raw Q, presence of bioB-/C-/D-spikes, 
GAPDH and ACTB 3’ to 5’ ratio, thus the array 
quality could be controlled. Because our data 
were from the online database, no informed 
consents would be needed.
Statistical analysis
We analyzed the relationship between PDCD-1 
and overall survival (OS) as well as CTLA-4 and 
OS using Cox’s proportional hazards regression 
model. Hazard Ratio, 95% CI and logrank P 
were calculated. Then the analysis was restrict-
ed to different subtypes by stage, histology, 
grade and P53 mutation and association of 
each category with OS was also presented 
with entire reported data online (see Table 2). 
Gene expression level was compared using 
the H-Test (Kruskal-Wallis) and U test (Mann-
Whitney) (see Table 3). All the above analyses 
were conducted using the SPSS software (ver-
sion 19.0 Chicago, IL, USA).
Results
The Kaplan Meier plotter databases include 
1,648 ovarian cancer patients with a mean fol-
low-up of 40 months. The Overall survival anal-
ysis was run on 1,582 patients meeting our 
criteria. Altogether, 77, 65, 1005 and 169 
patients were stage I, II, III, and IV; 1143 
patients were serous cancer, whereas 36 were 
endometrioid cancer; the number of people in 
Grade 0, 1, 2, 3, 4 were 10, 56, 315, 973, 2; 
441 patients had P53gene mutation, in con-
trast to 87 wild types. Mean expression value, 
(±) 95% Confidence Interval, Standard Error 
and standard Deviation were analyzed. A sum-
mary of the clinical characteristics of the data-
base is presented in Table 1 and Figure 1. 
Grade 0 and 4 patients were excluded because 
of relatively small numbers of patients enrolled 
in the database. Mean CTLA-4 expression value 
was higher in endometrioid, compared with 
serous cancer patients (mean value 53.95 vs. 
64.75).
Low expressions of PDCD-1 and CTLA-4 were 
associated with poor outcomes
Using KMplot software, PDCD-1 and CTLA-4 
gene expressions among 1582 ovarian cancer 
patients were shown with median gene expres-
sion value as the cut-off. The number of patients 
Table 2. Prognostic roles of PDCD-1 and CTLA-4 in ovarian cancer patients and subgroup analysis
PDCD-1 CTLA-4
Low Expres-
sion (n)
High Expres-
sion (n)
Hazard 
Ratio 95% CI
logrank 
P
Low Expres-
sion (n)
High Expres-
sion (n)
Hazard 
Ratio 95% CI
logrank 
P
Entire cohort 792 790 0.06 0.77-1.01 0.06 803 779 0.84 0.73-0.96 0.01 
Stage
    1 44 30 0.69 0.21-2.29 0.54 37 37 1.30 0.41-4.11 0.65 
    2 43 16 0.74 0.2-2.73 0.65 33 26 0.62 0.19-2.02 0.42 
    3 576 406 0.83 0.7-0.99 0.04 568 414 0.78 0.66-0.93 0.01 
    4 74 92 1.22 0.83-1.81 0.31 67 99 0.82 0.56-1.2 0.31 
Subtype (1_serous2_endometrioid)
    1 728 410 0.91 0.77-1.07 0.27 571 567 0.91 0.78-1.07 0.91 
    2 22 14 1.16 0.19-6.94 0.87 9 27 0.22 0.04-1.32 0.07 
Grade
    1 168 162 1.70 0.88-3.31 0.11 28 28 1.03 0.39-2.73 0.94 
    2 159 156 0.91 0.67-1.23 0.53 158 157 0/81 0.59-1.1 0.18 
    3 496 472 0.95 0.8-1.13 0.60 491 477 0.89 0.75-1.05 0.16 
P53 mutation (1_mutated, 0_wild type)
    0 45 41 1.37 0.76-2.49 0.29 45 41 0.94 0.52-1.68 0.83 
    1 224 215 1.08 0.84-1.39 0.56 222 217 0.90 0.7-1.16 0.43 
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with lower PDCD-1 expression was 792, and 
the number with higher was 790 (see Table 2). 
We observed that shorter OS in those patients 
with low gene expressions (see Figure 2). In 
detail, higher expression of the PDCD-1 was not 
significantly correlated with better OS with HR 
0.88 (95% CI: 0.77-1.01) but higher CTLA-4 was 
associated with better survival with HR 0.84 
(95% CI: 0.73-0.96) on the transcriptome level.
In addition, by utilizing an extended version of a 
database of public microarray datasets (http://
kmplot.com/analysis), which is meta-analysis 
based biomarker assessment software, we 
generated Kaplan-Meier curves (see Figure 2). 
We also drew the bee swarm plot using the 
bee swarm package (www.cbs.dtu.dk/weklund/
beeswarm/). The bee swarm plot can visualize 
gene expression as non-overlapping points in a 
one-dimensional scatter plot which is useful in 
identifying outlier samples and genes with 
bimodal distribution.
Comparison of gene expression level
The non-parametric (see Table 3) tests, H-Test 
(Kruskal-Wallis) and U test (Mann-Whitney) 
were used to compare gene expression level. 
Expression of PDCD-1 and CTLA-4 did not differ 
with regard to stages and P53 gene mutation. 
But the expression of CTLA-4 was higher in 
endometrioid than in serous cancer patients. 
H-Test (Kruskal-Wallis) showed that different 
grades of both PDCD-1 and CTLA-4 had differ-
ent mean values.
Discussion
In this study with a large number of patients, 
we found that lower CTLA-4 was associated 
with poorer survival (HR 0.84, 95% CI: 0.73-
0.96, P=0.0099), but the relationship between 
expression of PDCD-1 and survival (HR: 0.88, 
95% CI: 0.77-1.01, P=0.061) was not statisti-
cally significant. Although significant improve-
ment has been achieved in the new chemother-
apeutical agents in the therapy of ovarian can-
cer and the 5-year survival rate has been 
increasing, the mortality of this malignant dis-
ease remains unchanged [6], current treatment 
strategies are still far from optimum, and we 
can only improve OS by identifying more robust 
targets [17].
Table 3. Gene expression level comparison using H-Test (Kruskal-Wallis) and U test (Mann-Whitney)
PDCD-1 CTLA-4
H-Test (Kruskal-Wallis)
Patient 
Number
Mean 
Rank
H Degrees of 
Freedom
P 
Value
Patient 
Number
Mean 
Rank
H Degrees of 
Freedom
P 
Value
Stage 1 77 683.27 3.27 3.00 0.35 77 735.38 4.43 3.00 0.22 
2 65 605.68 65 658.24 
3 1004 665.14 1004 657.50 
4 169 624.16 169 625.60 
U-Test (Mann-Whitney)
N Mean 
Rank
U Z P N Mean 
Rank
U Z P
Subtype (1_serous2_
endometrioid)
1 1143 586.99 17131.50 1.71 0.09 1143 585.46 15386.50 2.58 0.01 
2 36 685.63 24016.50 36 734.10 25761.50 
H-Test (Kruskal-Wallis)
N Mean 
Rank
H Degrees of 
Freedom
P N Mean 
Rank
H Degrees of 
Freedom
P
Grade
0 10 722.40 23.68 4.00 <0.01 10 787.10 26.67 4.00 <0.01
1 56 725.68 56 714.97 
2 315 767.10 315 771.66 
3 973 646.48 973 645.61 
4 2 762.50 2 444.50 
U-Test (Mann-Whitney)
N Mean 
Rank
U Z P N Mean 
Rank
U Z P
P53 mutation (1_mu-
tated, 0_wild type)
0 87 258.15 18631.00 -0.43 0.67 87 255.90 18435.50 -0.58 0.56 
1 441 265.75 19736.00 441 266.20 19931.50 
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The functions of PDCD-1 and CTLA-4’s co-
expression were shown in four aspects: PDCD-
1 and CTLA-4 were associated with obvious 
dysfunction of antigen-specific T cells, blocking 
PDCD-1 and CTLA-4 pathways reversed T cell 
dysfunction, adoptive transfer of CD8+CTLA-
4+PDCD-1+TILs that had previously been treat-
ed in vitro with αPDCD-1 and αCTLA-4 anti- 
bodies eliminated tumors, and lastly, block- 
ade of PDCD-1/PD-L1 pathway in regulatory T 
cells attenuates their suppressive function 
[15]. Cause tumor cells are known to develop 
immune escape mechanisms to camouflage 
themselves from the surveillance of our human 
bodies, either by down-regulating the activity of 
T-cells through activation of the inhibitory T-cell 
receptors CTLA-4 and PDCD-1 or promoting 
Treg cell activity, they will tip the balance 
between pro- and anti-immunoactivity towards 
inhibition of T-cells.
Pioneering studies established that both CD4+ 
and CD8+ T cells lacking CTLA-4 in vitro and 
in vivo presented high proliferation and an 
activated phenotype from the work of laborato-
ries of Allison, Bluestone, and others [18-23]. 
Figure 1. PDCD-1 and CTLA-4 expression based on (A) stage, (B) subtype, (C) grade and (D) P53 mutation. Histo-
gram plot error bar represents 95% CI.
Figure 2. Overall survival curves of PDCD-1 and CTLA-4 gene expressions andbee swarm plot. Red color represents 
high gene expression; black color represents low expression. PDCD-1 is shown on the left side; CTLA-4 is shown on 
the right side.
PDCD-1 and CTLA-4
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What’s more, a significant body of data sug-
gests that inhibitors of immune checkpoints 
might have significant utility in treating cancer 
which has been borne out by the US FDA’s 
approvals of two different antibodies against 
PDCD-1 and CTLA-4, respectively [24]. Antibody- 
mediated blockade of PDCD-1 and CTLA-4 aug-
mented T-cell immune responses, and the use 
of an antibody against CTLA-4 in combination 
with a cytokine-expressing cellular vaccine was 
capable of inducing recession of already-estab-
lished poorly immunogenic tumors like B16 
melanoma [25].
Based on the theories mentioned above, PDCD-
1 and CTLA-4 expressions should be positively 
associated with ovarian cancer patients. How- 
ever, according to our meta-analysis, the HR 
was 0.88 (95% CI: 0.77-1) for PDCD-1 and 0.85 
(95% CI: 0.74-0.97) for CTLA-4, respectively. 
Lower expressions of the two genes were not 
significantly correlated with longer relapse-free 
survival and vice versa. The paradox may be 
due to the highly sophisticated immunore- 
gulatory pathways involving PDCD-1, CTLA-4, 
and their ligands [26-29]. The complexity of 
each pathway and cross-talk between them 
and the interactions with other pathways make 
it not so simple in human body. 
In a study performed by Li Jiang [30], positive 
PD-L1 expression showed a trend toward being 
independently correlated with longer OS (P= 
0.080), perhaps due to different choice of cut-
point values, and different tumors have differ-
ent biologic behaviors with the systemic immu-
nologic environment affecting the tumor growth 
to varying degrees.
In advanced gastric adenocarcinoma patients, 
it was found that higher up-regulated PD-L1 
expression had much better prognosis than 
low expression patients (65.6% vs. 44.7%, P= 
0.028). Patients with higher sPD-L1 expression 
had better overall survival, perhaps because of 
different strategies in selecting the study popu-
lation and different kinds of test methods [31].
The association of PD-L1 expression with favor-
able outcome has also been observed in lung 
cancer [32, 33], colon cancer [34], Merkel cell 
carcinoma [35], and melanoma [36]. 
What’s more, analysis of the transcriptome via 
microarray did not account for the multiple lay-
ers of regulation present in the process of tran-
scription, translation, and protein function. All 
the results were based on transcriptome which 
may have different functions after processing 
in human body.
There are some limitations related to our work. 
First, although this is the largest up-to-date 
research on the prognostic roles of PDCD-1 and 
CTLA-4, this study lacks long-enough follow-up 
data and therefore the impact of both PDCD-1 
and CTLA-4 on prognosis could not be accu-
rately evaluated. Second, we did not perform 
Q-PCR or microarray analysis to substantiate 
the main conclusions. Additional limitation is 
the intrinsic property of the database, as it 
does not show the complicated process pres-
ent in translation or protein function. Hence, to 
optimally identify the role of PDCD-1 and CTLA-
4, careful delineation of the gene interactions 
in vivo and its relationship with the tumor 
microenvironment is crucial.
In conclusion, we found that lower expression 
of CTLA-4, but not PDCD-1 predicts worse 
survival. The development of molecular bio-
markers will beneficially allow the selection of 
those patients who may benefit from novel 
therapeutic agents against standard therapeu-
tic approaches. However, further large-scale, 
more comprehensive analyses need to be car-
ried out. Our current findings still merit further 
investigation.
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